Neil Versel is a staff reporter at GenomeWeb. He covers the life science and healthcare informatics markets.
After more than two years of development, the British vendor has matched HPC for sequencing alignment accuracy, at far lower power consumption.
Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
Startups offering blockchain technology to support genomics and precision medicine still need to prove themselves and find markets.
GenePattern Notebook, online since April, is meant to aggregate text, graphics, and computer code for analysis against the GenePattern bioinformatics database.
Blockchain technology, most commonly associated with Bitcoin, could potentially solve scalability and trust issues often associated with genomic data.
Geneformics, which grew out of Israel's Weizmann Institute, promises to boost the speed of moving data by tenfold and cut costs by 90 percent.
"It's actually pretty difficult to build an artificially intelligent machine," according to a top Google life scientist, who is more focused on iterative machine learning.
This small, for-profit Dutch company has been a driving force behind freeing cBioPortal from Memorial Sloan Kettering, as well as continued development of the software.
The $10 million donation from Mark Zuckerberg and Priscilla Chan should accelerate data sharing and alleviate shortage in bioinformatics expertise.
The open-source MultiQC software platform aggregates multiple bioinformatics analyses into a single report for the purpose of quality control.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.